Generics Bulletin is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aurobindo Expects Sandoz Business To Over-Perform

Executive Summary

Aurobindo is betting that its $1bn purchase of Sandoz’ US assets will beat its earlier expectations and help to fuel significant growth for the Indian firm. It expects the acquisition, the company’s biggest ever, to close within 8-12 weeks.

Advertisement

Related Content

Aceto Claims That Aurobindo Caused Its Collapse
Slowing Biopharmaceuticals Puts A Dent In Sandoz’ Sales
Aurobindo Acquires Seven Oncology Injectables From Spectrum
US Pricing Pressures Have Stabilized, Insists Teva Chief
Aurobindo snaps up US businesses from Sandoz
Aurobindo buys Europe operations from Apotex

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

GB140402

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel